- Home
- WATT vs PMCB Comparison
WATT vs PMCB Comparison
Compare WATT & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- PMCB
- Stock Information
- Founded
- WATT 2012
- PMCB 1996
- Country
- WATT United States
- PMCB United States
- Employees
- WATT N/A
- PMCB N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WATT Technology
- PMCB Health Care
- Exchange
- WATT Nasdaq
- PMCB Nasdaq
- Market Cap
- WATT 10.0M
- PMCB 10.5M
- IPO Year
- WATT 2014
- PMCB N/A
- Fundamental
- Price
- WATT $0.48
- PMCB $1.66
- Analyst Decision
- WATT Strong Buy
- PMCB
- Analyst Count
- WATT 2
- PMCB 0
- Target Price
- WATT $2.25
- PMCB N/A
- AVG Volume (30 Days)
- WATT 18.4M
- PMCB 15.7K
- Earning Date
- WATT 11-12-2024
- PMCB 03-17-2025
- Dividend Yield
- WATT N/A
- PMCB N/A
- EPS Growth
- WATT N/A
- PMCB N/A
- EPS
- WATT N/A
- PMCB 0.74
- Revenue
- WATT $431,184.00
- PMCB N/A
- Revenue This Year
- WATT $95.75
- PMCB N/A
- Revenue Next Year
- WATT $834.07
- PMCB N/A
- P/E Ratio
- WATT N/A
- PMCB $2.25
- Revenue Growth
- WATT N/A
- PMCB N/A
- 52 Week Low
- WATT $0.28
- PMCB $1.39
- 52 Week High
- WATT $2.75
- PMCB $2.58
- Technical
- Relative Strength Index (RSI)
- WATT 46.32
- PMCB 53.60
- Support Level
- WATT $0.49
- PMCB $1.50
- Resistance Level
- WATT $1.44
- PMCB $1.75
- Average True Range (ATR)
- WATT 0.22
- PMCB 0.11
- MACD
- WATT -0.06
- PMCB 0.01
- Stochastic Oscillator
- WATT 1.55
- PMCB 53.35
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.